Navega Therapeutics is a preclinical stage company developing epigenetic gene therapies for neurological and ophthalmic diseases.
Navega Therapeutics has raised $4.0M in total funding. The most recent round was Grant. The last funding was announced in February 2025.
Navega Therapeutics's investors include Creative Destruction Lab, California Institute for Regenerative Medicine, National Cancer Institute, National Institute of Neurological Disorders and Stroke.
Navega Therapeutics is headquartered in San Diego, United States.
Navega Therapeutics is a preclinical stage company developing epigenetic gene therapies for neurological and ophthalmic diseases.
Navega Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Navega Therapeutics — Funding & Investors." VCBacked, February 4, 2025, https://www.vcbacked.co/company/navega-therapeutics. Accessed September 30, 2026.
VCBacked. (2025). Navega Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/navega-therapeutics
{{cite web |title=Navega Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/navega-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated